On the stock market since 2019, it operates in the world of health and science. It has 34,100 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
Average growth of 19% a year over the last 4 years. Every year shown ended in profit.
The gap is $15.5B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 18% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The stock sits at $0.12. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, CELG-RI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CELG-RI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.